| __timestamp | Alnylam Pharmaceuticals, Inc. | Bio-Techne Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 30945000 |
| Thursday, January 1, 2015 | 276495000 | 40853000 |
| Friday, January 1, 2016 | 382392000 | 45187000 |
| Sunday, January 1, 2017 | 390635000 | 53514000 |
| Monday, January 1, 2018 | 505420000 | 55329000 |
| Tuesday, January 1, 2019 | 655114000 | 62413000 |
| Wednesday, January 1, 2020 | 654819000 | 65192000 |
| Friday, January 1, 2021 | 792156000 | 70603000 |
| Saturday, January 1, 2022 | 883015000 | 87140000 |
| Sunday, January 1, 2023 | 1004415000 | 92493000 |
| Monday, January 1, 2024 | 1126232000 | 96664000 |
Cracking the code
In the ever-evolving world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Alnylam Pharmaceuticals and Bio-Techne Corporation have demonstrated contrasting approaches to R&D investment. Alnylam's R&D expenses have surged by over 400% from 2014 to 2023, reflecting its aggressive pursuit of groundbreaking therapies. In contrast, Bio-Techne's R&D budget has grown by approximately 200%, indicating a more measured approach.
Alnylam's R&D spending reached its peak in 2023, with a notable increase of 14% from the previous year. Meanwhile, Bio-Techne's steady growth culminated in a 9% rise in 2023. These trends highlight the diverse strategies within the biotech sector, where innovation is paramount. Missing data for 2024 suggests ongoing developments, leaving room for future insights.
Research and Development: Comparing Key Metrics for Gilead Sciences, Inc. and Alnylam Pharmaceuticals, Inc.
GSK plc vs Alnylam Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. vs Madrigal Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Galapagos NV
Genmab A/S vs Bio-Techne Corporation: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Bio-Techne Corporation vs Alpine Immune Sciences, Inc.
R&D Spending Showdown: Bio-Techne Corporation vs Verona Pharma plc
R&D Insights: How Bio-Techne Corporation and Catalyst Pharmaceuticals, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Bio-Techne Corporation and PTC Therapeutics, Inc.
Bio-Techne Corporation or Viridian Therapeutics, Inc.: Who Invests More in Innovation?